$1.49
arrow_drop_up1.01%Key Stats | |
---|---|
Open | $1.50 |
Prev. Close | $1.48 |
EPS | -1.31 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $38.17M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 1.46 | 1.55 |
52 Week Range | 0.89 | 5.33 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.31 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Autonomix Medical (NASDAQ:AMIX), Absci ... - Benzinga
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference